Clinical Trials, Research and Development
June 16, 2022
Via: PharmaphorumThe result isn’t a big surprise – Roche terminated two phase 3 trials of crenezumab in people with prodromal to mild sporadic Alzheimer’s in early 2019 after interim analyses found it would be futile to continue – but is another […]
Clinical Trials, Research and Development
June 14, 2022
Via: PharmaphorumChina’s emergence as an R&D powerhouse means that the country is quickly adding a number of drug candidates to the global pipeline. Despite more treatment options being a positive, Ben Hargreaves finds that this has raised issues over single-region clinical […]
Cell and Gene Therapy, Industry
June 13, 2022
Via: Contract PharmaCoave Therapeutics, a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS (Central Nervous System) and eye diseases, and ABL, a pure play contract development and manufacturing organization (CDMO) specialized in the development and manufacturing of viruses for […]
June 2, 2022
Via: Biopharma DiveThe most immediate effect of the deal is a much-needed infusion of funds for Repare, which went public in 2020 at a price of $20 a share. The company’s stock soared above $42 in early 2021, only to plummet as […]
Cell and Gene Therapy, Industry
June 1, 2022
Via: FierceBiotechBioMarin’s commercial aspirations for its hemophilia gene therapy remain on ice after the FDA lobbed additional questions for the company to address, pushing back an expected approval submission to September. BioMarin was vague on what the FDA is asking for, […]
Cell and Gene Therapy, Industry
May 27, 2022
Via: FierceBiotechMost cancer immunotherapies primarily rely on T cells to neutralize tumors. But in two new studies, scientists at Dana-Farber Cancer Institute and Stanford University have described novel immuno-oncology approaches, showing that leveraging other components of the immune system may achieve […]
Clinical Trials, Research and Development
May 26, 2022
Via: Drugs.comMoleculin Biotech, Inc., (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced the commencement of dosing in its first-in-human Phase 1a study to evaluate the […]
Clinical Trials, Research and Development
May 23, 2022
Via: FiercePharmaSix weeks after slapping a clinical hold on a trial of Ocugen’s COVID-19 vaccine, the FDA has lifted it. That’s the good news for the Malvern, Pa. company, which has partnered with India’s Bharat Biotech on the shot known commercially […]
Cell and Gene Therapy, Industry
May 20, 2022
Via: FierceBiotechBayer is pulling the plug on its $670 million CAR-T pact with Atara Biotherapeutics. Three months after a death paused a study of the lead candidate, the German drugmaker has decided to cut its ties to Atara’s two mesothelin-directed CAR-T […]
Clinical Trials, Research and Development
May 20, 2022
Via: FierceBiotechThe FDA has sounded a warning about Foghorn Therapeutics’ blood cancer candidate FHD-286, putting a phase 1 clinical trial on a partial hold in response to the death of a patient with potential differentiation syndrome. FHD-286 is an enzymatic inhibitor […]
Cell and Gene Therapy, Industry
May 19, 2022
Via: FierceBiotechSyncona is continuing to bet big on gene therapy. While setbacks at other biotechs have taken the sheen off the modality, the investor is keeping the faith in SwanBio Therapeutics, stepping up to provide the lion’s share of a $56 […]
Cell and Gene Therapy, Industry
May 18, 2022
Via: Contract PharmaAt a dedication of the new Jeffrey Leiden Center for Cell and Genetic Therapies in Boston’s Seaport, Vertex Pharmaceuticals unveiled plans to build another 344,000 square foot facility in the Seaport to support the company’s growth of its cell and […]
May 31, 2022
June 16, 2022
Copyright © 2022. All rights reserved
